Cas:914349-45-4 3-(2-Aminopyrimidin-5-yl)benzoic acid manufacturer & supplier

We serve Chemical Name:3-(2-Aminopyrimidin-5-yl)benzoic acid CAS:914349-45-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(2-Aminopyrimidin-5-yl)benzoic acid

Chemical Name:3-(2-Aminopyrimidin-5-yl)benzoic acid
CAS.NO:914349-45-4
Synonyms:fc0625
Molecular Formula:C11H9N3O2
Molecular Weight:215.20800
HS Code:2933599090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:552.7ºC at 760 mmHg
Density:1.379
Index of Refraction:1.668
PSA:89.10000
Exact Mass:215.06900
LogP:2.00520

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like fc0625 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,fc0625 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,fc0625 Use and application,fc0625 technical grade,usp/ep/jp grade.


Related News: Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. 3-(2-Aminopyrimidin-5-yl)benzoic acid manufacturer Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. 3-(2-Aminopyrimidin-5-yl)benzoic acid supplier Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. 3-(2-Aminopyrimidin-5-yl)benzoic acid vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. 3-(2-Aminopyrimidin-5-yl)benzoic acid factory Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.